Genitourinary Cancers

Fruquintinib plus sintilimab significantly extended progression-free survival in advanced RCC following first-line VEGFR TKI therapy.

Randy F. Sweis, MD, discusses potential toxicities and mitigation strategies associated with the bispecific T-cell engager XmAb819.

Preview the top lung, breast, GI, GU, gynecologic, and hematologic oncology abstracts and topics ahead of the 2025 ESMO Congress.

The FDA approved adjuvant cemiplimab in cutaneous squamous cell carcinoma, issued a CRL to dasatinib in chronic myeloid leukemia, and more.

Randy F. Sweis, MD, explains the mechanism of action of the ENPP3/CD3–targeted bispecific T-cell engager XmAb819 in renal cell carcinoma.

Check out this September recap of OncLive’s coverage of the top news and expert insights renal cell carcinoma.

Experts in genitourinary oncology share key insights on the most anticipated data and abstracts expected to shape discussions at the 2025 ESMO Congress.

Karie Runcie, MD, discusses the mechanism of action of XmAb30819 in clear cell RCC.

Phase 2 data showed bevacizumab plus erlotinib active in papillary RCC, with 72% responses in HLRCC-associated and 35% in sporadic disease.

A real-world analysis shows avelumab plus axitinib is safe and effective in advanced RCC.

Randy F. Sweis, MD, discusses the potential utility of ENPP3 as a therapeutic target in RCC.

The addition of the PD-1 inhibitor to platinum-based chemotherapy demonstrated proof of concept for the use of chemoimmunotherapy in patients with PSCC.

ENPP3 offers a potentially attractive treatment target in patients with clear cell RCC.

OncLive social media polls reveal which prostate, kidney, and bladder cancer abstracts are generating excitement ahead of the 2025 ESMO Congress.

Real-world data highlighted differences in the timing and severity of belzutifan-related toxicities in VHL-associated tumors and sporadic RCC.

Vote in OncLive's polls to share which lung and genitournary cancer abstracts you're most anticipating at the 2025 ESMO Congress.

The FDA approved subcutaneous pembrolizumab for use in adult and pediatric solid tumor indications approved for intravenous pembrolizumab.

Sumanta Pal, MD, FASCO, explained the rationale for evaluating atezolizumab vs placebo for the treatment of patients with high-risk localized RCC.

Alexander Chehrazi-Raffle, MD, discusses the rationale for a subgroup analysis of the TiNivo-2 of tivozanib with/without nivolumab in mRCC.

Jad Chahoud, MD, MPH, discusses the safety profile of ALLO-316 for the treatment of patients with advanced clear cell renal carcinoma.

Jad Chahoud, MD, MPH, discusses the CAR T-cell therapy ALLO-316 in advanced clear cell renal carcinoma (ccRCC).

The top 5 OncLive videos of the week cover insights in sarcoma, colorectal cancer, acute lymphoblastic leukemia, renal cell carcinoma.

Jad Chahoud, MD, MPH, discusses preliminary efficacy data with zanzalintinib plus nivolumab with/without relatlimab in untreated, advanced clear cell RCC.

Naomi B. Haas, MD, details the rationale for evaluating adjuvant pembrolizumab monotherapy for the treatment of patients with clear cell RCC.

Hans Hammers, MD, PhD, discusses factors that may influence depth of response to IO/TKI or IO/IO therapy in advanced clear cell renal cell carcinoma.